Theravance Biopharma, Inc. Capital Expenditures
Theravance Biopharma, Inc. (TBPH) reported Capital Expenditures of $2.13 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2017-03-01
- Theravance Biopharma, Inc. payments to acquire property, plant, and equipment for the quarter ending 2016-06-30 was $638.00K, a 10.14% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire property, plant, and equipment for the quarter ending 2016-03-31 was $684.00K, a 4.11% increase year-over-year.
- Theravance Biopharma, Inc. payments to acquire property, plant, and equipment for the quarter ending 2015-12-31 was $606.00K, a 20.78% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire property, plant, and equipment for the quarter ending 2015-09-30 was $674.00K, a 46.20% increase year-over-year.
- Theravance Biopharma, Inc. payments to acquire property, plant, and equipment for fiscal 2016 was $2.13M, a 19.34% decline from fiscal 2015.
- Theravance Biopharma, Inc. payments to acquire property, plant, and equipment for fiscal 2015 was $2.65M, a 14.81% decline from fiscal 2014.
- Theravance Biopharma, Inc. payments to acquire property, plant, and equipment for fiscal 2014 was $3.11M, a 13.64% increase from fiscal 2013.
- Theravance Biopharma, Inc. payments to acquire property, plant, and equipment for fiscal 2013 was $2.73M, a 5.56% increase from fiscal 2012.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2016-12-31 | $2.13M 10-K · filed 2017-03-01 | |||
| 2016-06-30 | $638.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $1.32M 10-Q · filed 2016-08-09 | $1.93M derived: sum of 3 quarters · filed 2017-03-01 | $2.60M derived: sum of 4 quarters · filed 2017-03-01 |
| 2016-03-31 | $684.00K 10-Q · filed 2016-05-10 | $1.29M derived: sum of 2 quarters · filed 2017-03-01 | $1.96M derived: sum of 3 quarters · filed 2017-03-01 | $2.67M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-12-31 | $606.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $1.28M derived: sum of 2 quarters · filed 2017-03-01 | $1.99M derived: sum of 3 quarters · filed 2017-03-01 | $2.65M 10-K · filed 2017-03-01 |
| 2015-09-30 | $674.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $1.38M derived: sum of 2 quarters · filed 2016-08-09 | $2.04M 10-Q · filed 2015-11-12 | $2.81M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $710.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $1.37M 10-Q · filed 2016-08-09 | $2.13M derived: sum of 3 quarters · filed 2017-03-01 | $2.59M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $657.00K 10-Q · filed 2016-05-10 | $1.42M derived: sum of 2 quarters · filed 2017-03-01 | $1.88M derived: sum of 3 quarters · filed 2017-03-01 | $2.14M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $765.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $1.23M derived: sum of 2 quarters · filed 2017-03-01 | $1.49M derived: sum of 3 quarters · filed 2017-03-01 | $3.11M 10-K · filed 2017-03-01 |
| 2014-09-30 | $461.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $722.00K derived: sum of 2 quarters · filed 2015-11-12 | $2.34M 10-Q · filed 2015-11-12 | $3.41M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $261.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $1.88M 10-Q · filed 2015-08-13 | $2.95M derived: sum of 3 quarters · filed 2016-03-11 | $3.18M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $1.62M 10-Q · filed 2015-05-13 | $2.69M derived: sum of 2 quarters · filed 2016-03-11 | $2.92M derived: sum of 3 quarters · filed 2016-03-11 | $3.61M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $1.30M derived: sum of 2 quarters · filed 2016-03-11 | $1.99M derived: sum of 3 quarters · filed 2016-03-11 | $2.73M 10-K · filed 2016-03-11 |
| 2013-09-30 | $237.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $928.00K derived: sum of 2 quarters · filed 2014-11-12 | $1.67M 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $691.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $1.43M 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $740.00K 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | $2.59M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |